Eosinophilia as a predictor of response to checkpoint inhibition in patients with metastatic melanoma.

Eosinophilia as a predictor of response to checkpoint inhibition in patients with metastatic melanoma.

Blog Article

Immune checkpoint inhibitors can prolong survival and lead to cure in metastatic melanoma.Baseline indices have not proven clinically useful as predictors of response.Identifying early treatment response would have clinical and ilootpaperie economic benefits.

The Christchurch Hospital Oncology Department maintains a prospective registry of melanoma patients treated with pembrolizumab and nivolumab.Patients were classified as either alive-and-progression-free (responders) or as dead-or-progressive-disease (non-responders).Thirty-six patients were included.

Median follow-up was 16 months (range 1-41 months).Twelve patients died and 3 had progressive disease.Mean eosinophils were 0.

168x109/L in responders and 0.198x109/L in non-responders (p=0.565).

In responders, eosinophil count significantly increased after three treatments to 0.37x109/L (p=0.009).

There was a significant difference in the change in eosinophil count between responders and non-responders, p=0.02.In this small study, response to immune checkpoint inhibitors was sensationnel kiyari associated with increased eosinophils.

This finding may help predict subsequent clinical response and may help in assessment of suspected pseudo-progression.